Ageless Biotech, Inc.
Developer of adipose-derived and minimally manipulated tissue regenerative biologics for intra-articular treatment of osteoarthritis. The company describes proprietary, patent-pending processing and device technologies to extract and manufacture cell- and tissue-based therapeutics (including stromal vascular fraction from adipose tissue) and is planning Phase 2b multisite clinical evaluation. The organization highlights in-house regulatory, clinical development, manufacturing/QA and R&D experience drawn from team members with prior IND/NDA/BLA and GxP work.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Investigational intra-articular regenerative biologic for knee osteoarthritis (Phase 2b)
An investigational biologic derived from adipose- and minimally manipulated post-birth/fetal tissues intended for intra-articular administration to treat moderate-to-severe knee osteoarthritis; subject of planned Phase 2b safety/tolerability studies.
Investigational intra-articular regenerative biologic for knee osteoarthritis (Phase 2b)
An investigational biologic derived from adipose- and minimally manipulated post-birth/fetal tissues intended for intra-articular administration to treat moderate-to-severe knee osteoarthritis; subject of planned Phase 2b safety/tolerability studies.
Services
Planning and operational execution of Phase 2b multisite clinical studies for intra-articular regenerative biologics addressing knee osteoarthritis.
Regulatory submission support (IND/IDE/NDA/BLA, device filings), QA systems development, GxP auditing and training delivered by experienced regulatory professionals on the team.
Planning and operational execution of Phase 2b multisite clinical studies for intra-articular regenerative biologics addressing knee osteoarthritis.
Regulatory submission support (IND/IDE/NDA/BLA, device filings), QA systems development, GxP auditing and training delivered by experienced regulatory professionals on the team.
Expertise Areas
- Cell therapy and regenerative medicine
- Adipose-derived biologics (SVF-based therapies)
- Clinical trial design and management (Phase 2b multisite)
- Regulatory compliance and submissions (FDA/EMA) including IND/NDA/BLA and device filings
Key Technologies
- Stromal Vascular Fraction (SVF) processing
- Adipose-derived cell therapy methods
- Minimally manipulated tissue processing
- Exosome and extracellular matrix–based biologics
News & Updates
Company blog post discussing the scope of biologics beyond stem cells.
Company blog post explaining HLA typing in the context of stem cell implantation.
Company states it uses proprietary, patent-pending processing technologies and device intellectual property for extraction, manufacture and delivery of biologic products.
Company blog post discussing the scope of biologics beyond stem cells.
Company blog post explaining HLA typing in the context of stem cell implantation.
Company states it uses proprietary, patent-pending processing technologies and device intellectual property for extraction, manufacture and delivery of biologic products.